Program
Valsartan
Also written as “valsartan”, “sacubitril/valsartan” and “valsartan plus hydrochlorothiazide”.
Its studies are mostly in Hypertension · Essential Hypertension · Heart Failure · Diabetes Mellitus, Type 2 · Proteinuria, led by 14 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 1060 open or running | phase 4since Sep 10, 2005 | Nov 30, 2004 | none ahead |
| LG Chem | 50 open or running | phase 3since Aug 5, 2013 | May 11, 2010 | none ahead |
| IlDong Pharmaceutical | 20 open or running | phase 3since May 20, 2014 | May 20, 2014 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | no phasesince Jul 21, 2014 | Jul 21, 2014 | none ahead |
| ARKAY Therapeutics | 10 open or running | phase 2since Sep 23, 2018 | Sep 23, 2018 | none ahead |
| Dexa Medica Group | 10 open or running | no phasesince Aug 3, 2015 | Aug 3, 2015 | none ahead |
| EMS | 10 open or running | phase 3since Nov 23, 2015 | Nov 23, 2015 | none ahead |
| farma-de-colombia-sa | 10 open or running | phase 3since May 7, 2013 | May 7, 2013 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Jul 30, 2015 | Jul 30, 2015 | none ahead |
| Hanlim Pharm. | 10 open or running | phase 1since Aug 2, 2018 | Aug 2, 2018 | none ahead |
| JW Pharmaceutical | 10 open or running | phase 1since Jul 26, 2011 | Jul 26, 2011 | none ahead |
| Lunan Pharmaceutical Group | 11 open or running | phase 3since Mar 4, 2025 | Mar 4, 2025 | Dec 2027phase 3 · NCT06863987 |
| tsh-biopharm-corporation-limited | 10 open or running | phase 4since Feb 4, 2014 | Feb 4, 2014 | none ahead |
| Yuhan | 10 open or running | phase 1since Jan 5, 2012 | Jan 5, 2012 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb, GlaxoSmithKline and Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 22, 2007.
- Jan 15, 2015Phase 1 study in HypertensionIlDong Pharmaceutical · NCT02343250 · 54 enrolled
- Jul 30, 2015Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT02519010 · 36 enrolled · Egypt
- Aug 3, 2015Dexa Medica Group's first study: no phase study in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT02518451 · 48 enrolled · Indonesia
- Nov 23, 2015EMS's first study: phase 3 study in HypertensionNew to EMSEMS · NCT02662894
- Feb 23, 2017Phase 3 study in Cardiovascular DiseasesNovartis · NCT03066804 · 2,572 enrolled · United States, Argentina, Austria and more
- May 8, 2018Phase 1 study in Healthy Male VolunteersLG Chem · NCT03532854 · 42 enrolled · Korea, Republic of
- Aug 2, 2018Hanlim Pharm.'s first study: phase 1 study in HypertensionNew to Hanlim Pharm.Hanlim Pharm. · NCT03648333 · 27 enrolled
- Sep 23, 2018ARKAY Therapeutics's first study: phase 2 study in Diabetes Mellitus, Type 2New to ARKAY TherapeuticsARKAY Therapeutics · NCT03686657 · United States
- Dec 20, 2018Phase 3 study in Heart FailureNovartis · NCT03785405 · 216 enrolled · United States, Argentina, Austria and more
- Jun 13, 2019Phase 3 study in Heart Failure With Preserved Ejection Fraction (HFpEF)Novartis · NCT03988634 · 467 enrolled · United States, Canada
- Jul 10, 2019Phase 4 study in Chagas DiseaseNovartis · NCT04023227 · 922 enrolled · Argentina, Brazil, Colombia and more
- Nov 4, 2020Phase 3 study in Post Myocardial InfarctionNovartis · NCT04637555
- Nov 13, 2023Phase 3 study in Heart FailureNovartis · NCT06149104 · 8 enrolled · Japan
- Mar 4, 2025Lunan Pharmaceutical Group's first study: phase 3 study in Essential HypertensionNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06863987 · 342 planned · China
Ahead
- Dec 2027Primary completion: phase 3 study in Essential HypertensionLunan Pharmaceutical Group · NCT06863987
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Telmisartanrule | Boehringer Ingelheim | phase 4 | 132 |
| Losartanrule | Organon | phase 4 | 58 |
| azilsartan medoxomilrule | Takeda | phase 4 | 25 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
The newest 60 of 125 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06863987Essential Hypertension · China | 3 | By invitation | Lunan Pharmaceutical Group | Dec 2027 | 342 |
| NCT06149104Heart Failure · Japan | 3 | Completed | Novartis | Aug 14, 2024 | 8 |
| NCT04637555Post Myocardial Infarction | 3 | Withdrawn | Novartis | Jun 1, 2023 | 0 |
| NCT04023227Chagas Disease · Argentina, Brazil, Colombia and more | 4 | Completed | Novartis | Mar 16, 2025 | 922 |
| NCT03988634Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Canada | 3 | Completed | Novartis | Dec 14, 2022 | 467 |
| NCT03785405Heart Failure · United States, Argentina, Austria and more | 3 | Completed | Novartis | Dec 29, 2023 | 216 |
| NCT03686657Diabetes Mellitus, Type 2 · United States | 2 | Withdrawn | ARKAY Therapeutics | Dec 26, 2030 | 0 |
| NCT03648333Hypertension | 1 | Completed | Hanlim Pharm. | Feb 2014 | 27 |
| NCT03532854Healthy Male Volunteers · Korea, Republic of | 1 | Completed | LG Chem | Aug 25, 2018 | 42 |
| NCT03066804Cardiovascular Diseases · United States, Argentina, Austria and more | 3 | Completed | Novartis | Oct 28, 2019 | 2,572 |
| NCT02662894Hypertension | 3 | Withdrawn | EMS | Sep 2020 | 0 |
| NCT02518451Healthy · Indonesia | – | Completed | Dexa Medica Group | Oct 2013 | 48 |
| NCT02519010Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Mar 2011 | 36 |
| NCT02343250Hypertension | 1 | Completed | IlDong Pharmaceutical | Mar 2015 | 54 |
| NCT02197494Healthy · India | – | Completed | Sun Pharmaceutical Industries | Feb 2014 | 40 |
| NCT02197442Healthy · India | – | Completed | Sun Pharmaceutical Industries | Feb 2014 | 36 |
| NCT02145104Hypertension · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Jun 7, 2016 | 286 |
| NCT02062645Essential Hypertension · Turkey | 4 | Completed | Novartis | Sep 2015 | 115 |
| NCT02058446Essential Hypertension · Taiwan | 4 | Completed | tsh-biopharm-corporation-limited | Mar 2014 | 36 |
| NCT01928628Hypertension · Korea, Republic of | 3 | Completed | LG Chem | Apr 2013 | 449 |
| NCT01918358Hypertension · Korea, Republic of | 1 | Completed | LG Chem | Jan 2013 | 60 |
| NCT01918332Hypertension · Korea, Republic of | 3 | Completed | LG Chem | Mar 2013 | 168 |
| NCT01850160Hypertension · Colombia, Ecuador | 3 | Completed | farma-de-colombia-sa | Mar 2015 | 124 |
| NCT01617681Hypertension · Belgium, Brazil, France and more | 3 | Completed | Novartis | Jan 24, 2017 | 127 |
| NCT01541189Hypertension · China | 4 | Completed | Novartis | Jan 2013 | 200 |
| NCT01609907Hypertension · Korea, Republic of | 1 | Completed | Yuhan | May 2012 | 30 |
| NCT01447485Hypertension · Japan | 1 | Completed | Novartis | Oct 2011 | 12 |
| NCT01406431Hyperlipidemias · Korea, Republic of | 1 | Completed | JW Pharmaceutical | Aug 2011 | 48 |
| NCT01365481Hypertension · Colombia, Finland, Germany and more | 3 | Completed | Novartis | Sep 2015 | 150 |
| NCT01281306Isolated Systolic Hypertension · United States, Argentina, Canada and more | 2 | Completed | Novartis | Dec 2011 | 910 |
| NCT01241487Essential Hypertension · Egypt | 4 | Completed | Novartis | Jan 2011 | 150 |
| NCT01167153Hypertension · China | 4 | Completed | Novartis | Apr 2011 | 564 |
| NCT01122251Essential Hypertension · Korea, Republic of | 2 | Completed | LG Chem | May 2010 | 441 |
| NCT01001572Essential Hypertension | 3 | Completed | Novartis | May 2010 | 932 |
| NCT00939588Hypertension · Russian Federation | 2 | Completed | Novartis | Dec 2009 | 88 |
| NCT00931710Isolated Systolic Hypertension · United States | 4 | Completed | Novartis | Jan 2010 | 488 |
| NCT00902304Hypertension · United States, Australia | 4 | Completed | Novartis | Jul 2011 | 2,337 |
| NCT00821574Hypertension | 4 | Completed | Novartis | Mar 2007 | 144 |
| NCT00809926Hypertension · United States | 4 | Completed | Novartis | Jul 2009 | 451 |
| NCT00698646Hypertension · United States | 4 | Completed | Novartis | Jun 2009 | 384 |
| NCT00699192Hypertension · Czech Republic, Finland, France and more | 3 | Completed | Novartis | May 2009 | 965 |
| NCT00666536Hypertension · United States | 4 | Completed | Novartis | Jan 2009 | 728 |
| NCT00687973Hypertension · France | 4 | Completed | Novartis | Jan 2009 | 393 |
| NCT00700271Hypertension · France, Tunisia | 4 | Completed | Novartis | Aug 2008 | 478 |
| NCT00550095Proteinuria · Egypt | 4 | Completed | Novartis | Nov 2009 | 509 |
| NCT00548067Hypertension · India | 3 | Completed | Novartis | 111 | |
| NCT00523744Hypertension · Germany | 3 | Completed | Novartis | Dec 2007 | 257 |
| NCT00523549Hypertension · United States | 4 | Completed | Novartis | Jan 2008 | 229 |
| NCT00487123Hypertension · Singapore | 4 | Completed | Novartis | Sep 2007 | |
| NCT00457626Hypertension · United States, Belgium, Brazil and more | 3 | Completed | Novartis | May 25, 2009 | 66 |
| NCT00446563Hypertension · Germany | 3 | Completed | Novartis | Mar 2010 | 90 |
| NCT00446524Hypertension · Japan | 3 | Completed | Novartis | Oct 2008 | 403 |
| NCT00446511Hypertension · United States, Belgium, France and more | 3 | Completed | Novartis | Jun 2009 | 250 |
| NCT00439738Hypertension · United States | 4 | Completed | Novartis | Nov 2007 | 412 |
| NCT00437645Essential Hypertension · Argentina, Chile, Ecuador and more | 3 | Completed | Novartis | Nov 2007 | 1,183 |
| NCT00435162Hypertension · United States, Belgium, Brazil and more | 3 | Completed | Novartis | Jan 2009 | 74 |
| NCT00433836Hypertension · United States, Belgium, France and more | 3 | Completed | Novartis | Feb 2009 | 300 |
| NCT00426478Hypertension · Taiwan | 4 | Completed | Novartis | 80 | |
| NCT00425997Hypertension · United States | 4 | Completed | Novartis | Oct 2007 | 480 |
| NCT00425373Essential Hypertension · Japan | 3 | Completed | Novartis | Mar 2008 | 1,474 |
How it is read
Names in the registry
- “Valsartan”, 31 entries
- “valsartan”, 23 entries
- “sacubitril/valsartan”, 5 entries
- “valsartan plus hydrochlorothiazide”, 5 entries
- “valsartan + amlodipine”, 5 entries
Conditions, from the studies’ own filings
- Hypertension, 98 studies
- Essential Hypertension, 10 studies
- Heart Failure, 8 studies
- Diabetes Mellitus, Type 2, 5 studies
- Proteinuria, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.